Magle Chemoswed Holding AB (publ) (STO:MAGLE)

Market Cap	92.92M -86.2%
Revenue (ttm)	287.55M +19.5%
Net Income	-159.89M
EPS	-7.74
Shares Out	20.65M
PE Ratio	n/a
Forward PE	3.21
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,740
Average Volume	8,043
Open	4.560
Previous Close	4.500
Day's Range	4.500 - 4.560
52-Week Range	3.680 - 30.000
Beta	0.51
RSI	36.11
Earnings Date	Jun 9, 2026

About STO:MAGLE

Magle Chemoswed Holding AB (publ), together with its subsidiaries, engages in research and development of pharmaceutical and medical device products in Sweden. It provides warfarin sodium products used as anticoagulants for multiple indications; melperone hydrochloride, which is an antipsychotic agent; isradipine, a calcium channel blocker used to treat hypertension; and benserazide hydrochloride, which is used in combination with L-Dopa in the treatment of Parkinson’s disease. The company also offers EmboCept S, a microsphere-based medical dev...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1944
• Employees: 140
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: MAGLE